CANCER CHEMOPREVENTION - A REVIEW OF ONGOING CLINICAL-STUDIES

被引:6
作者
COSTA, A
SANTORO, G
ASSIMAKOPOULOS, G
机构
[1] The Istituto Nazionale Tumori, Milan
关键词
Alkaloids; Anti-oxidants; Cancer; Carotenoids; Chemoprevention; Hormones; Indoles; Retinoids; Selenium; Vitamins;
D O I
10.3109/02841869009090071
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The mass of experimental data on various possibilities of inhibiting the carcinogenic process is growing rapidly. However, the biological complexity of carcinogenesis and the intrinsic limitations of the animal models make it often very difficult to identify the real potentially effective agents among the hundreds currently being proposed. In fact, more than 600 potentially chemopreventive agents have been identified and approximately 30 of them are presently being tested in humans. The great heterogeneity of these compounds (they belong to over 20 different classes of chemicals) might be a positive feature as it indicates that a variety of approaches is possible and that the options for selecting effective compounds will be numerous. In recent years, what could be called clinical chemoprevention (that is controlled studies to evaluate in human subjects the efficacy of potentially chemopre-ventive agents) has developed considerably: according to American estimates 4 chemopreventive agents were tested clinically in 1981, 10 in 1985 and 18 in 1988. The number of reported preclinical investigations was 10 in 1985 and 75 in 1988. This rapid expansion has obviously led to some confusion in terminology and in the evaluation of primary results; at present there is still a need for further investigations to better define clinical chemoprevention and to differentiate it from chemotherapy. ©1990 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted.
引用
收藏
页码:657 / 663
页数:7
相关论文
共 33 条
[1]  
BERTRAM JS, 1987, CANCER RES, V47, P3013
[2]  
CLARK LC, 1985, FED PROC, V44, P422
[3]   TOLERABILITY OF THE SYNTHETIC RETINOID FENRETINIDE (HPR) [J].
COSTA, A ;
MALONE, W ;
PERLOFF, M ;
BURANELLI, F ;
CAMPA, T ;
DOSSENA, G ;
MAGNI, A ;
PIZZICHETTA, M ;
ANDREOLI, C ;
DELVECCHIO, M ;
FORMELLI, F ;
BARBIERI, A .
EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1989, 25 (05) :805-808
[4]  
CUZICK J, 1986, LANCET, V1, P83
[5]   A RANDOMIZED CLINICAL-TRIAL EVALUATING TAMOXIFEN IN THE TREATMENT OF PATIENTS WITH NODE-NEGATIVE BREAST-CANCER WHO HAVE ESTROGEN-RECEPTOR POSITIVE TUMORS [J].
FISHER, B ;
COSTANTINO, J ;
REDMOND, C ;
POISSON, R ;
BOWMAN, D ;
COUTURE, J ;
DIMITROV, NV ;
WOLMARK, N ;
WICKERHAM, DL ;
FISHER, ER ;
MARGOLESE, R ;
ROBIDOUX, A ;
SHIBATA, H ;
TERZ, J ;
PATERSON, AHG ;
FELDMAN, MI ;
FARRAR, W ;
EVANS, J ;
LICKLEY, HL ;
KETNER, M .
NEW ENGLAND JOURNAL OF MEDICINE, 1989, 320 (08) :479-484
[6]  
FORMELLI F, 1989, CANCER RES, V49, P6149
[7]   LIPOSOLUBLE VITAMINS AND LIPID PARAMETERS IN BREAST-CANCER - A JOINT STUDY IN NORTHERN ITALY AND SOUTHERN FRANCE [J].
GERBER, M ;
CAVALLO, F ;
MARUBINI, E ;
RICHARDSON, S ;
BARBIERI, A ;
CAPITELLI, E ;
COSTA, A ;
DEPAULET, AC ;
DEPAULET, PC ;
DECARLI, A ;
PASTORINO, U ;
PUJOL, H .
INTERNATIONAL JOURNAL OF CANCER, 1988, 42 (04) :489-494
[8]  
GREENBERG ER, 1989, CONTROL CLIN TRIALS, V10, P153
[9]   13-CIS-RETINOIC ACID IN THE TREATMENT OF ORAL LEUKOPLAKIA [J].
HONG, WK ;
ENDICOTT, J ;
ITRI, LM ;
DOOS, W ;
BATSAKIS, JG ;
BELL, R ;
FOFONOFF, S ;
BYERS, R ;
ATKINSON, EN ;
VAUGHAN, C ;
TOTH, BB ;
KRAMER, A ;
DIMERY, IW ;
SKIPPER, P ;
STRONG, S .
NEW ENGLAND JOURNAL OF MEDICINE, 1986, 315 (24) :1501-1505
[10]   EFFECT OF TAMOXIFEN (ICI 46,474) ON INITIATION AND GROWTH OF DMBA - INDUCED RAT MAMMARY CARCINOMATA [J].
JORDAN, VC .
EUROPEAN JOURNAL OF CANCER, 1976, 12 (06) :419-424